1175 YH006, a fully human Treg-depleting CTLA-4×OX40 bispecific antibody, demonstrates superior preclinical efficacy and favorable developability
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |